About Us
Improving Quality of Life for Peritoneal Dialysis Patients
Opterion Health is focused to bring innovation to dialysis and foster peritoneal dialysis (PD).
We aim to improve the quality of life for patients, their caregivers and loved ones as well as attempt to increase the survival rates of people who suffer from chronic kidney disease.
Opterion Health was founded in 2012 by healthcare experts. The Company, based in Switzerland, is one of the few research-driven companies developing a novel PD solution. Opterion Health is privately held and financed by private as well as institutional investors.
The new Opterion dialysis solution is the first innovation in PD in the last two decades and will not only improve patients’ well-being by offering flexibility at work and at home, but also reduce dialysis-related healthcare costs.
The new PD solution is glucose-free, considerably decreasing metabolic challenges and offers an innovative dialysis option for those patients who suffer from diabetes (approx. 45% of dialysis patients).
Opterion Health is a preclinical life science company with two novel approaches in development, based on known molecules. Our two-fold approach will increase the medical utility of PD by offering a better osmotic driver (ODR) and – possibly in combination – a biocompatibility-enhancing agent (BCA).
- Over 10% of the worldwide population suffers from Chronic Kidney Disease (CKD).
- ESRD patients must undergo kidney replacement therapy – either kidney transplantation (25%) or dialysis (75%).
- Approximately 45% of dialysis patients suffer from diabetes.
- The global dialysis market is estimated to be worth USD 80bn.
- Over 10% of the worldwide population suffers from Chronic Kidney Disease (CKD).
- Over 1% of the worldwide population will become End Stage Renal Disease (ESRD) patients.
- ESRD patients must undergo kidney replacement therapy – either kidney transplantation (25%) or dialysis (75%).
- Approximately 45% of dialysis patients suffer from diabetes.
- The global dialysis market is estimated to be worth USD 80bn.